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Christopher McKevitt7, John Murray8, Caroline Watkins9, Katie Powers1, Angela Shone10 and Amanda Farrin2Abstract
Background: Return to work (RTW) is achieved by less than 50% of stroke survivors. The rising incidence of stroke
among younger people, the UK economic forecast, and clinical drivers highlight the need for stroke survivors to
receive support with RTW. However, evidence for this type of support is lacking. This randomised controlled trial
(RCT) will investigate whether Early Stroke Specialist Vocational Rehabilitation (ESSVR) plus usual care (UC) (i.e. usual
NHS rehabilitation) is more clinically and cost-effective for supporting post-stroke RTW, than UC alone.
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Methods: Seven hundred sixty stroke survivors and their carers will be recruited from approximately 20 NHS stroke
services. A 5:4 allocation ratio will be employed to randomise participants to receive ESSVR plus UC, or UC alone. The
individually tailored ESSVR intervention will commence within 12 weeks of stroke onset and be delivered for up to 12
months as necessary by trained RETAKE occupational therapists in the community, participants’ homes or workplaces,
and outpatient/inpatient therapy settings, via telephone, email, or SMS text message. Outcome data will be collected
via self-report questionnaires administered by post or online at 3, 6, and 12months follow-up. The primary outcome
will be self-reported RTW and job retention at 12months (minimum 2 h/week). Secondary outcomes will include
mood, function, participation, health-related quality of life, confidence, intervention compliance, health and social care
resource use, and mortality. An embedded economic evaluation will estimate cost-effectiveness and cost-utility
analyses from National Health Service (NHS) and Personal Social Services (PSS) perspectives. An embedded process
evaluation will employ a mixed methods approach to explore ESSVR implementation, contextual factors linked to
outcome variation, and factors affecting NHS roll-out.
Discussion: This article describes the protocol for a multi-centre RCT evaluating the clinical- and cost-effectiveness of
an early vocational rehabilitation intervention aimed at supporting adults to return to work following a stroke. Evidence
favouring the ESSVR intervention would support its roll-out in NHS settings.
Trial registration: ISRCTN, ISRCTN12464275. Registered on 26 February 2018.
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Background and rationale {6a}
The UK incidence of stroke has increased among
younger people, with an estimated 41% occurring among
those aged under 69 years [1]. Nearly two thirds of
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[2], resulting from physical, cognitive, and/or language
impairments [3, 4]. Return to work (RTW) is a major
goal for many stroke survivors, but less than 50% of
those working at stroke onset return [5], often due to
the limitations posed by residual disabilities [3, 4], their
beliefs [6], employer attitudes [7], and access to timely
rehabilitation [8]. Vocational rehabilitation (VR) is a
process that supports those disadvantaged by illness or
disability to access, return to, and maintain employment
or another useful occupation [9].
Work is essential for supporting health, wellbeing, and
longevity [10], and protects against social exclusion by
providing an income, social interaction, a core role,
identity, and purpose [10, 11]. Conversely, long-term
worklessness has been linked to increased risk of depres-
sion, suicide, reduced quality of life, cardiovascular dis-
ease, and health-harming behaviours [11, 12]. The societal
cost of stroke has been estimated at £26 billion per year,
including £8.6 billion for health and social care [13]. These
costs will likely increase due to strokes occurring at earlier
ages, improvements in survival rates, and changes in re-
tirement age provisions [1, 14]. The effects on the UK
economy may be further compounded by rises in un-
employment resulting from the COVID-19 pandemic
[15]. The need for support for stroke survivors with RTW
is already recognised in policy and clinical guidelines [16–
23] and is considered a UK government priority and Na-
tional Health Service (NHS) outcome [24–26]. Despite
this, there has been little evidence reported for the effect-
iveness of post-stroke VR interventions. A systematic re-
view (2011) of VR post-stroke [27] identified only one
randomised controlled trial (RCT) in the United States
(US) (N = 22, 7 people with stroke) that used a case-
coordination approach, leading to 64% employment com-
pared to 36% in usual care (UC) at 6months [28]. In a
subsequent RCT in South Africa (N = 94), a 6-week work-
place intervention delivered by an occupational therapist
(OT) and physiotherapist led to 60% employment at 6
months compared with 20% in UC [29]. However, both
RCTs were conducted in non-UK settings with small sam-
ple sizes; an adequately powered RCT is needed to repli-
cate the results in UK NHS settings.
Early Stroke Specialist Vocational Rehabilitation (ESSV
R) was developed from VR practice recommendations in
acquired brain injury [17] and guidance from stroke
specialists, VR experts, and stroke survivors. ESSVR
combines conventional OT with case coordination [30]
and is intended for delivery in the community as often as
required by individuals, as determined by a stroke
specialist OT with additional VR training. ESSVR includes
the following: (a) assessing stroke impact on the person
and their job; (b) educating individuals, employers, and
families about stroke impact on work, and strategies tolessen impact (e.g. memory aids, fatigue management); (c)
work preparation, including opportunities to practice
work skills; and (d) liaison with employers and
employment advisors to plan and monitor a phased return
to work (RTW).
In a single-centre feasibility RCT, ESSVR was com-
pared to usual NHS rehabilitation (UC) in previously
employed stroke survivors [31]. In total, 46 out of 92 eli-
gible participants agreed to participate (36 men, mean =
56 years, SD = 12.7). Among these, 34 (74%) had mild-
to-moderate strokes, and 32 (70%) were followed up at
12 months follow-up. The study showed it is possible to
recruit from an acute stroke unit, randomise to the trial,
deliver ESSVR, and measure its effects and costs at 3, 6,
and 12 months post-stroke. In the ESSVR group, twice
as many people were in work at 12 months post-stroke
than with UC, and those in work were less depressed,
suggesting potential health benefits [32]. However, this
was a small single-centre feasibility RCT, so it is un-
known whether observed differences were related to
ESSVR or due to chance.
The rising incidence of stroke among younger adults,
the UK economic forecast, and clinical drivers highlight
the need for stroke survivors to receive support with
RTW. However, lack of evidence for the clinical- and
cost-effectiveness of stroke-specialist VR has hindered
the development and commissioning of VR services [31].
In 2015, only 27% of Clinical Commissioning Groups
(CCGs) in the UK commissioned VR services within
acute stroke service providers [33]. An adequately pow-
ered multi-centre study is needed to inform the clinical-
and cost-effectiveness of ESSVR and UC, alongside a
process evaluation (methods to be reported elsewhere)
exploring contextual factors affecting clinical implemen-
tation and RTW outcomes. Evidence in favour of the
ESSVR intervention would support its roll-out within
the NHS.
The aim of the RETAKE trial is to evaluate the
clinical- and cost-effectiveness of ESSVR (plus UC) ver-
sus UC alone for helping people return to work after
stroke. The null hypothesis is that there is no difference
between ESSVR (plus UC) versus UC alone.Objectives {7}
The primary objective of this study is to establish
whether ESSVR (plus UC) is more effective than UC
alone for improving participants’ self-reported RTW (≥
2 h per week) at 12 months post-randomisation.
The secondary objectives include the following:
 To investigate whether the intervention leads to
improvement in self-reported work outcomes, in-
cluding (a) RTW with the same employer, (b)
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of days worked.
 To investigate whether the intervention improves
mood, physical function, participation, health-related
quality of life, work self-efficacy, and post-stroke
confidence.
 To determine whether the intervention changes
overall health (including accident and emergency
visits, inpatient admissions, outpatient visits, and
primary care use including medications) and social
care resource use.
 To estimate the likely cost-effectiveness of the inter-
vention compared to UC alone, from the perspective
of the NHS and Personal Social Services (PSS).
 To establish whether the intervention reduces carer
burden.Trial design {8}
This trial protocol has been reported in line with the
Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) checklist [34]. RETAKE is
a pragmatic, multi-centre, superiority randomised con-
trolled trial (RCT) with two parallel groups, and a par-
tially nested trial design with embedded internal pilot
and economic and process evaluations. The internal
pilot will include 8 sites and will assess whether progres-
sion criteria thresholds are met for recruitment rates
after 6 months of recruitment and for follow-up rates
after 12 months of recruitment (see the ‘Recruitment
{15}’ section for further details).
The intervention arm will receive ESSVR in addition
to UC, and the intervention will be delivered by ESSVR-
trained OTs. This approach has been taken to demon-
strate it is feasible to provide the ESSVR intervention as
part of routine care across the wider NHS, if benefit is
demonstrated. Participants in the UC only arm will re-
ceive UC provided by primary care, secondary care,
community, and social services.Methods: participants, interventions, and
outcomes
Study setting {9}
Participants will be recruited from approximately 20 NHS
stroke services across the UK, including hyper acute
stroke units, acute stroke units, stroke rehabilitation units,
and linked early supportive discharge and community
rehabilitation services. The ESSVR intervention will be
delivered one-to-one, face-to-face in the community, in
the participant’s home or workplace, in an outpatient
therapy setting, or in hospital (when the participant is hos-
pitalised for a long period of time), or via telephone, post,
email, or SMS text message.Eligibility criteria {10}
Participant eligibility
Those meeting all of the following criteria will be
eligible to participate in the study:
Inclusion criteria
 Age 18 years or over at time of the stroke
 Admitted to hospital with a new stroke (all
severities)
 In work at stroke onset (including self-employed,
paid, or unpaid)
 Willing and have capacity to provide informed
consent to participate in the study
 Sufficient proficiency in English language to
contribute to the data collection required
Participants with a language barrier resulting from
stroke (e.g. aphasia) will still be considered eligible, as
long as capacity to provide consent can be established.
Local sites will seek assistance from family members or
suitably trained independent clinical professionals, to
ensure that individuals satisfying the eligibility criteria
can be included wherever possible.
Exclusion criteria
 Not intending to workCarer eligibility
A carer will be defined as a main informal caregiver who
provides the participant with support a minimum of
once per week. Carers meeting the following inclusion
criteria will be eligible to participate in the study:
Inclusion criteria
 Nominated carer of consenting participant
 Willing and have capacity to provide informed
consent to participate in the study
 Sufficient proficiency in English language to
contribute to the data collection requiredSite identification and eligibility
Stroke services will be eligible to take part if they meet
the following eligibility criteria:
Inclusion criteria
 Stroke service able to deliver ESSVR
 Agreement by therapy service managers that a site
recruitment target of 2 participants per month is
feasible
 Agreement by therapy service managers that ESSV
R-trained therapists will not treat participants in the
UC only arm
Exclusion criteria
 Sites that routinely provide well-defined and active
vocational rehabilitation for participants within 12
weeks of stroke
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OTs experienced in delivering community rehabilitation
programmes and/or specialist stroke rehabilitation to
stroke survivors will be identified by the site to receive
training and to deliver the intervention.
Who will take informed consent? {26a}
The Principal Investigator (PI) at each site will ensure
that anyone responsible for the informed consent
process is authorised, trained, and competent according
to the ethically approved protocol, principles of Good
Clinical Practice (GCP) [35], and Declaration of Helsinki
(1996) [36].
Written informed consent will be required prior to the
participant undergoing study procedures. The PI or their
nominee will explain study details and provide the
information sheet (Additional file 1). The PI or nominee
will answer questions, ensuring the participant has
sufficient time to consider their participation. Where a
participant is unable to sign their name or mark the
consent form (Additional file 2), they will be asked for
verbal consent to participate, as observed by an
independent witness such as a staff member, relative, or
friend, who will then sign and date the form. Aphasia-
friendly versions of participant materials (Additional files
3 and 4) will be utilised where appropriate.
Approach and informed consent of carers
During recruitment or at the baseline assessment,
consenting participants will be asked if they wish to
nominate a carer to participate in the study. Carers will
only be approached if they have been nominated, and
the participant has verbally consented to them being
approached. Nominated carers will be provided with a
study information sheet (Additional file 5) (with
covering letter and consent to follow-up leaflet if sent to
their home address) informing them about the study.
Research staff will meet with interested carers to answer
any questions, and obtain written informed consent
(Additional file 6).
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
Participants will be asked to consent to the secure
sharing of identifiable information with the Department
for Work and Pensions to request information relating
to work status (Additional files 2 and 4).
Additional informed consent will be sought from a
randomly selected 5% of participants and their carers (if
nominated) from both study arms, and from an
additional 5% of ESSVR participants as part of the
study’s embedded process evaluation. Further details will
be reported in the protocol for the RETAKE process
evaluation.Interventions
Explanation for the choice of comparators {6b}
Usual care (UC)
The study protocol will not restrict access to UC, in line
with the pragmatic trial design [37] and the possibility of
heterogeneity for UC treatments for stroke survivors.
UC will be available to both intervention and UC
(control) participants and will consist of usual NHS
rehabilitation provided by primary care, secondary care,
community, and social services, as determined by local
policies and procedures. It is likely to include General
Practitioner (GP) appointments for medical problems,
rehabilitation for activities of daily living (e.g. washing
and dressing, toileting, cooking, driving/transport use),
and use of voluntary sector services.Intervention description {11a}
ESSVR (plus UC)
ESSVR is an early, individually tailored intervention
delivered by stroke specialist OTs who have undergone
training delivered by experienced OTs from the central
RETAKE team during site set-up. The 2-day face-to-face
training package includes provision of an ESSVR man-
ual, clinical scenarios, and case studies to support learn-
ing for the delivery of ESSVR. The RETAKE OTs will be
briefed via group discussion and case studies on the tri-
al’s design, paperwork to be completed, and issues relat-
ing to delivery of the intervention within the trial
context. Throughout the study duration, RETAKE OTs
will receive a 1-day refresher training day, monthly
group mentoring sessions, and ad hoc individualised
support via email or telephone.
RETAKE OTs will initiate communication with ESSV
R participants via telephone or letter. The content, dose
(e.g. number of sessions), intensity, and duration of the
intervention will be individually tailored according to
participants’ needs, their preferences, and employment
context.
RETAKE OTs will follow the ESSVR manual and
record delivery of content, duration, and dose on Case
Reporting Forms (CRFs) and routine treatment records.
Assessments and intervention will include the following:
 Assessing the impact of stroke on the participant
and their job
 Educating patients, employers, and families about
stroke impact on work
 Finding strategies to lessen impact, e.g. memory
aids, pacing to conserve energy
 Work preparation, including establishment of
routines and opportunities to practice work skills
(e.g. use of computers to increase concentration,
walking to increase physical stamina)
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plan and monitor a phased RTW (as needed for up
to 12 months post-randomisation)
Criteria for discontinuing or modifying allocated
interventions {11b}
Withdrawal
Prior to provision of consent, it will be explained that
participant withdrawal from the study will not affect
their future care or benefits, but any data collected up to
that point will be included in analyses and cannot be
erased or omitted. Participants may be withdrawn from
the study at their own request or at the discretion of the
PI or nominee. At the time of withdrawal, it will be
clarified whether participants are withdrawing from the
intervention and/or data collection.
Strategies to improve adherence to interventions {11c}
Appointed mentors will assess and monitor RETAKE
OTs’ progress, skills, and competency to deliver the
intervention, and provide monthly telephone support at
individual or group level for up to an hour. RETAKE
OTs’ competency will be assessed via case vignettes at
the end of training and at 6 months post-randomisation.
At 12 months post-randomisation, competency will be
assessed through review of case notes for 1 randomly se-
lected participant per OT. Competency scores will indi-
cate whether additional training and mentoring support
is required. To account for staff turnover, further site-
level training will be available when required.
RETAKE OTs’ adherence to the ESSVR manual and
intervention delivery will be monitored via mentoring
records, content CRFs, and routine treatment records. A
fidelity checklist will be completed during observations
in a random 5% of cases. Further details of the study’s
process evaluation will be reported elsewhere.
Relevant concomitant care permitted or prohibited
during the trial {11d}
No restrictions will be imposed on UC or any other
concomitant care or interventions during the study
period.
Provisions for post-trial care {30}
No arrangements are in place for ancillary or post-trial
care beyond routine UC, nor for compensation for non-
negligent care occurring from study participation, as per
usual practice.
Outcomes {12}
There is no consensus in the literature about what
constitutes a successful work outcome. In this study, the
primary outcome will be self-reported return to work of
≥ 2 h per week at 12 months post-randomisation,including pre-stroke or new work roles. It will be mea-
sured via a positive response to the question, ‘Are you
currently in work (paid or unpaid) for at least 2 h per
week?’
Return to education was removed as part of the
primary outcome following inspection of data from the
feasibility trial [38], where only two participants were
full-time students at stroke onset, and following consult-
ation with the Patient and Public Involvement (PPI)
group. To reflect this change, the RETAKE trial’s inclu-
sion criteria were amended to increase the age of eligi-
bility from 16 to 18 years, excluding those in full-time
education (and not employed) prior to their stroke.
The secondary outcomes will be self-reported at 3, 6,
and 12 months post-randomisation, and will include re-
turn to with the same employer (yes/no, including self-
employed work), mean number of hours worked (to be
recorded as a proportion of the pre-stroke working
hours), total number of days in work, mood, functional
ability, social participation, health-related quality of life,
health and social care resource use, work self-efficacy,
and confidence.
Participant timeline {13}
A participant timeline was created according to SPIRIT
guidance [34] and is presented in Fig. 1. Following
admission into a stroke service, screening, informed
consent, and baseline assessments will be completed
within 12 weeks of stroke onset, prior to randomisation
and allocation. The ESSVR intervention will commence
within 2 weeks post-randomisation, and last as long as
needed up to 12 months post-randomisation. The start
and end dates within the UC control group will likely
vary, dependent on the usual NHS rehabilitation pro-
vided by each stroke service. Self-reported follow-up
questionnaires will be completed by all participants and
nominated carers at 3, 6, and 12 months post-
randomisation.
Sample size {14}
The planned study sample size is 760 participants (ESSV
R plus UC, 420; UC alone, 340). This provides 90%
power at the 5% significance level, to detect a 13%
absolute difference in the proportion of people in work
at 12 months (assuming 26% in control as per the
feasibility study) [32]. It accounts for 20% loss to follow-
up and clustering in the intervention arm to account for
therapist effects (11 recruited per RETAKE OT, 2 RE-
TAKE OTs per site, 20 sites, intra-cluster correlation co-
efficient (ICC) 0.03, inflation factor 1.234). Clustering
will only exist in the intervention arm to account for
between-therapist effects. An ICC of 0.03 has been as-
sumed, given that standardised training and manuals for
delivering the intervention will minimise the ICC. A
Fig. 1 Timeline of screening, recruitment, randomisation, interventions, and assessments
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ICC no greater than 0.03 [39, 40].
Recruitment {15}
Recruitment across sites will vary according to service
infrastructure and patient pathways. Discussions with
sites during site set-up will inform development of tai-
lored strategies to optimise identification and recruit-
ment of participants.
Descriptive data from 8 participating sites will be
summarised as part of an internal pilot, to assess
whether pre-defined progression criteria thresholds are
met at 6 months for recruitment and 12 months for
follow-up rates. These assessments will be based on a
traffic light system of green (go), amber (review), and
red (stop). The recruitment criterion will be a recruit-
ment rate of 2 patients per site per month (green), at
least one but less than two (amber), or less than one
(red). The follow-up criterion will be a follow-up rate of
at least 80% (green), at least 65% but less than 80%
(amber), or less than 65% (red). The Trial Steering Com-
mittee (TSC) will be provided with the data to inform
decisions concerning study continuation. A rescue plan
may be developed if significant recruitment and/or
follow-up issues are identified.
Screening
Following admission to the recruiting unit/service, the
patient’s UC team will work closely with experiencedand appropriately trained Clinical Research Network
(CRN)/local research staff to screen out clearly ineligible
patients. The patient’s UC will also provide detailed
information about the eligibility criteria for participation
in the trial, and will generate a list of potentially eligible
participants to track throughout admission and up to 12
weeks post-stroke. Anonymised screening logs will be
completed and returned to the Clinical Trials Research
Unit (CTRU) regularly to aid identification of recruit-
ment issues.Recruitment in hospital
Recruitment posters with contact details of research
staff will be displayed at each site. The UC team will
obtain verbal consent from potentially eligible
participants to be approached by a researcher.
Research staff will approach the patient (and carers if
appropriate) and discuss study participation. Those
showing interest will be given verbal and written
study information, and opportunities to ask questions.
They will be asked if they have a carer they wish to
nominate, and provided with carer involvement
information if appropriate.
The time period given for decisions to participate will
vary according to hospital length of stay, and
appropriate confirmation of eligibility, written informed
consent, and completion of baseline assessments will be
completed whilst the patient is still an inpatient.
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Patients expressing interest in the study, who have
provided consent to be followed up (by completion of
the consent to follow-up leaflet), may be discharged
from hospital prior to consent and baseline data collec-
tion. In these instances, they will be contacted by re-
search staff to arrange a visit at the patient’s home or
hospital to discuss the study further, confirm eligibility,
obtain informed consent, and complete the baseline
assessments.
In instances where patients were not approached
during their hospital stay, their UC team will review
their hospital notes for eligibility. Potentially eligible
participants will be sent a consent to follow-up leaflet,
covering letter, and study information, and asked to
complete and return the leaflet within 2 weeks if
interested.
Research staff and PIs (or nominees) across inpatient
and community settings will be responsible for
answering questions, confirming patients’ eligibility,
obtaining consent, and performing the baseline
assessment.
Carer recruitment
Carers will not be approached unless they have been
nominated by a participant, and the participant has
given verbal consent for them to be approached. Once
written informed consent has been obtained from the
carer, research staff will arrange to meet them within 2
weeks to perform the baseline assessment.
Assignment of interventions: allocation
Sequence generation {16a}
Participants will be individually randomised to ESSVR
(plus UC) or UC alone with a 5:4 allocation ratio. The
increased proportion allocated to the intervention arm
accounts for a greater level of correlation anticipated in
the outcomes for those receiving ESSVR, due to
participants being treated by the same OT staff. A 24-h
computer-generated minimisation programme will be
used for allocation, with incorporation of a random
element stratified by site, participant age (< 55, ≥ 55),
and stroke severity (derived from EQ5D mobility ques-
tion and Oxford Cognitive Screen (OCS) picture naming
and executive tasks).
Concealment mechanism {16b}
An automated email will be sent from the CTRU 24-h
randomisation service to research staff performing the
randomisation and the designated RETAKE OTs, con-
firming randomisation and the participant’s allocation.
The site PI will receive an automated email informing
them that the participant has been randomised, but no
allocation details will be revealed. Participants’ allocationdetails will only be revealed to PIs following confirm-
ation of the participant’s eligibility, informed consent,
and collection of their baseline data.
Implementation {16c}
The automated email from the CTRU will detail
participant identifiers, randomisation allocation, and
subsequent actions required. RETAKE OTs will attempt
to contact ESSVR participants to inform them of their
allocation; they will also keep a record of participants
allocated to UC to ensure RETAKE OTs do not treat
UC participants.
UC participants will be notified by CTRU of their
allocation via letter, with details of subsequent actions
(e.g. follow-up assessments). The CTRU will inform par-
ticipants’ GPs of study participation via letter, omitting
allocation details.
Assignment of interventions: blinding
Who will be blinded {17a}
Participants and the OTs delivering the intervention will
not be blind to allocation group. To minimise the risk of
detection bias, baseline data will be collected prior to
participant randomisation. Where possible, research staff
will be blinded to allocation when they contact
participants who have not returned postal/online follow-
up questionnaires (following reminder letters/emails).
GPs and the wider health and social care teams will be
blinded to participants’ allocation status. ESSVR-directed
contact with the GP and wider care teams is permitted
as part of the intervention. All reports to the Trial Man-
agement Group (TMG) and TSC will be presented in
blinded formats.
Procedure for unblinding if needed {17b}
If requested by the TMG or TSC (e.g. due to safety
concerns), CTRU will provide the relevant allocation
status. Where unforeseen unblinding occurs, site staff
will provide the CTRU with detailed information on
circumstances surrounding the incident.
Data collection and management
Plans for assessment and collection of outcomes {18a}
The planned timepoints and methods for outcome data
collection are summarised in Table 1.
Secondary outcomes not pertaining to work status or
days/hours worked will be measured using the following
assessment tools:
1. Mood, measured via the Hospital Anxiety and
Depression Scale [41] which has been shown to
have excellent internal consistency and construct
validity among stroke survivors [42].
Table 1 The planned timepoints and methods for outcome data collection
Assessment Type Method of
completion
Timeline
Screening Baseline 3
months
6
months
12
months
Participant data
Screening (demographics/assessment of eligibility) CRF Researcher X
Consent Consent form Self-
completion
X
Eligibility/location of baseline assessment CRF Researcher X
Demographics (age/gender/ethnicity/relationship status/home
circumstances/employment details/educational level/driving
status)
CRF Researcher X
Oxford Cognitive Screen (OCS) CRF Researcher X
Details of stroke CRF Researcher X
Relevant co-morbidities/medical issues Questionnaire
booklet
Researcher/
self-
completion
X X X X
Contact details (e.g. address/telephone numbers/preferred
method of contact/GP details/employer details)
CRF Researcher X
Change of contact details CRF Researcher/
OT/CTRU
Unscheduled (as made aware)
Work status Questionnaire
booklet
Researcher/
self-
completion
X X X X
Hospital Anxiety and Depression Scale (HADS) Questionnaire
booklet
Researcher/
self-
completion
X X X X
Nottingham Extended Activities of Daily Living (NEADL) Questionnaire
booklet
Researcher/
self-
completion
X X X X
Community Integration Questionnaire (CIQ) Questionnaire
booklet
Researcher/
self-
completion
X X X X
Health-related quality of life (EuroQol EQ-5D-5L) Questionnaire
booklet
Researcher/
self-
completion
X X X X
Resource use (primary care/secondary care/emergency care/
medications/social services/wider societal costs (e.g.
productivity costs, out of pocket costs))
Questionnaire
booklet
Researcher/
self-
completion
X X X X
Work self-efficacy (single question from the Work Ability Index) Questionnaire
booklet
Researcher/
self-
completion
X X X X
Confidence after Stroke Measure (CASM) Questionnaire
booklet
Researcher/
self-
completion
X X X X
Safety reporting Questionnaire
booklet/CRF
Researcher/
self-
completion
X X X
Work status (DWP) Routine data Data
transfer
DWP >
CTRU
Downloads to be agreed with DWP to
allow 12-month data collection
Usual care data CRF Researcher/
self-
completion
X X X X
Carer data
Consent Consent form Self-
completion
X
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Table 1 The planned timepoints and methods for outcome data collection (Continued)
Assessment Type Method of
completion
Timeline
Screening Baseline 3
months
6
months
12
months
Eligibility CRF Researcher X
Contact details (address/telephone numbers/preferred method
of contact/GP details)
CRF Researcher X
Carer demographics (age/gender/ethnicity/relationship to
participant/employment details)
Questionnaire
booklet
Researcher/
self-
completion
X X X X
Modified Caregiver Strain Index (MCSI) Questionnaire
booklet
Researcher/
self-
completion
X X X X
Health-related quality of life (EuroQol EQ-5D-5L) Questionnaire
booklet
Researcher/
self-
completion
X X X X
Resource use (health, social care, and personal costs) Questionnaire
booklet
Researcher/
self-
completion
X X X X
Questions relating to impact on carer’s work Questionnaire
booklet
Researcher/
self-
completion
X X X X
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Extended Activities of Daily Living index [43]. This
tool measures abilities to carry out instrumental
activities of daily living and has established validity
among stroke survivors [44].
3. Social participation, measured via the Community
Integration Questionnaire [45]. This tool is
designed to assess productivity, and home and
social integration following acquired brain injury,
and has been found to have acceptable internal
consistency [46].
4. Health-related quality of life, measured via the
EuroQol EQ-5D-5L [47] which records self-ratings of
health relating to mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression. It has been
shown to have construct and convergent validity
when tested on a stroke survivor population [48].
5. Health and social care resource use, measured via a
bespoke resource use questionnaire.
6. Work self-efficacy, measured via a single question
from the Work Ability Index [49], ‘Assume that
your work ability at its best has a value of 10 points.
How many points would you give your current
work ability?’
7. Confidence, measured via the Confidence after Stroke
Measure [50]. This tool measures positive attitudes,
confidence, and social confidence after stroke, and has
established validity and reliability [51].
Research staff will receive training to ensure
standardised completion of study-specific assessments.
Participants and nominated carers will have the optionto complete self-report questionnaires via post or online
using internet-based software called QTool.
Plans to promote participant retention and complete
follow-up {18b}
Priming calls, initial and reminder letters/emails, and
SMS prompts will be used to maximise data return at all
timepoints. A 2-way SMS text message will also be sent
(if mobile number provided) to confirm work status only
of stroke survivors. If there is no response, the CTRU
will alert research staff and, if possible, a blinded staff
member will attempt to contact the participant via tele-
phone or arrange a face-to-face visit to perform the
assessment.
Data management {19}
Data collection forms transferred to/from the CTRU will
be coded with a study number (made up of the
recruitment site code and the participant’s unique
sequential trial number), the participant’s initials, and
date of birth. Study data will be held securely on paper
and electronically at the University of Leeds’ CTRU, and
appropriate processes put in place for the transfer,
storage, restricted access, and disposal of personal
information. Relevant Standard Operating Procedures,
Guidelines and Work Instructions in relation to data
management, processing, and analysis of data will be
followed.
Confidentiality {27}
All study staff and investigators will endeavour to
protect the rights of the trial’s participants to privacy
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handled strictly in accordance with the consent
provided, adhering to the Data Protection Act 2018 [52]
at all times. Upon study completion, sites will archive all
study data until authorisation for confidential
destruction is provided by the study sponsor. Upon
study completion, the data shall be transferred from
CTRU to the University of Nottingham in an encrypted
format and stored for at least 7 years. The Trial Master
File and documents held by the CTRU will be archived
at secure facilities at the University of Nottingham and
University of Leeds.
Plans for collection, laboratory evaluation, and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
There are no plans for collection, laboratory evaluation,
or storage of biological specimens for this study.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
A detailed statistical analysis plan will be finalised and
agreed prior to analysis by the research team. No formal
interim analyses are planned. A single final analysis is
planned after the trial is closed to recruitment and
follow-up and when the full database has been cleaned
and locked. Analyses will be completed by the CTRU
statisticians using SAS software. Descriptive data (e.g.
total numbers of screened patients, patients eligible for
participation, those providing consent, reasons for non-
entry) will be reported. Baseline characteristics for each
study arm will be summarised.
The primary analysis will compare the proportions of
participants in work at 12 months post-randomisation
between arms, using a partially nested logistic regression
mixed-effects model accounting for clustering in the
intervention arm only, The model will adjust for stratifi-
cation factors (site, age, EQ5D mobility score, OCS pic-
ture naming score, OCS executive task score) as fixed
effects. Therapist (for those in intervention arm) and
treatment group will be fitted as random effects. If a par-
ticipant is unable to report their working status, e.g. if
they are dead, this will be taken as a negative response
to the question. Other missing data will be assumed
missing at random for the primary analysis; multiple im-
putation for handling such missing data will be explored
as a sensitivity analysis.
Analysis of secondary outcomes (return to work with
the same employer, number of hours worked per week,
number of days in work, mood, physical function,
community participation, work self-efficacy, post-stroke
confidence) at 3, 6, and 12 months will use a similar
modelling strategy to analyse secondary outcome data.Logistic or linear mixed-effects models will be fitted as
appropriate.
For all primary and secondary analysis models,
corresponding parameter estimates, standard errors,
hazard ratios, 95% confidence intervals, p values, and
ICC (in intervention) will be reported.
Interim analyses {21b}
No interim analyses are planned.
Methods for additional analyses (e.g. subgroup analyses)
{20b}
Baseline characteristics of those lost to follow-up will be
compared with those not lost to follow-up to assess for
bias. In addition to the intention to treat (ITT) analysis,
Complier Average Causal Effect (CACE) analyses will be
undertaken on the primary endpoint in order to measure
the impact of the intervention among participants who
complied with treatment. Parameter estimates for the
intervention effect can then be compared with those
from the ITT analysis to help better evaluate the effect
of the intervention. Several CACE models will be exam-
ined, using increasingly strict definitions of engagement.
The CACE models will use the same mixed-effects mod-
elling techniques used in the primary analysis to ensure
for reasonable comparisons to be made. Baseline charac-
teristics of those lost to follow-up at the 12-month time-
point will be compared with those not lost to follow-up
to assess for bias.
Methods for economic analysis
A within-trial economic evaluation (a cost-utility ana-
lysis) will be conducted comparing the costs and QALYs
in the ESSVR plus usual care group to usual care alone
group for participants of working age from the perspec-
tive of the UK NHS and PSS in the base case as recom-
mended [53] and from a wider perspective in secondary
analysis to reflect the expected wider costs and benefits
of the VR intervention.
The intervention resource use (comprising training,
mentoring, and delivery) will be captured and recorded
by the intervention OTs. This will be used to estimate
the cost of the training and mentoring components to
be used in the main economic evaluation. Levels of
wider health, PSS, and societal resource use at baseline,
3, 6, and 12 months will be captured using a bespoke
resource use questionnaire designed for self-completion
(or with help where required). Although intervention de-
livery costs will be estimated using data captured by the
OTs delivering the interventions, these will not be in-
cluded in the economic evaluation as it was felt by the
research team, which includes PPI members, that partic-
ipants would not be able to distinguish between inter-
vention OT visits and non-intervention OT visits such
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clude all visits in their responses to the resource use
questions. To avoid the potential for double counting,
we will therefore base resource use and costs on patient
reported data only with the exception of training and
mentoring costs. We will attach published national unit
costs using the common recent price year [54–56] to
individual-level quantities of resource use and estimate
the mean cost per participant incorporating the cost of
the intervention and wider healthcare and PSS resource
use (primary care, secondary care, emergency care, med-
ications, and social services). Secondary analysis will take
a wider cost perspective including participants, carers,
and employers and wider public sector services perspec-
tive where possible.
Health-related quality of life will be measured using
the EQ-5D-5L [47, 57] at baseline, 3, 6, and 12months,
and valued in line with guidance at the time of analysis
[58]. QALYs will be estimated for the trial period using
linear interpolation and area under the curve analysis,
adjusting for baseline values [59].
A regression-based approach (seemingly unrelated re-
gression equations) [60] will be used for the statistical
analysis if the necessary assumptions hold. The level of
uncertainty associated with the decision over which op-
tion is most cost-effective will be explored using non-
parametric bootstrapping [61] to construct the cost-
effectiveness acceptability curve (CEAC) [62]. Neither
costs nor QALYs will be discounted reflecting the time
frame of the trial. Missing data will be handled in line
with the approach reported by [63]. Where appropriate,
the economic analysis will take the same approach to
missing data as the clinical statistical analysis to ensure
consistency. Sensitivity analysis will explore the impact
of different ways of handling missing data.
The planned economic analysis is subject to change to
ensure it stays in line with any changes to accepted
methodology during the course of the study. A detailed
Health Economics Analysis Plan will be finalised and
reviewed by an independent health economist prior to
the trial database being locked.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
Analyses will be conducted on all randomised
participants, in the study arms to which they were
allocated, regardless of intervention non-adherence.
Missing data may occur at the item, scale, and timepoint
levels. Recommendations on handling of missing item
data from scoring protocols will be followed. Otherwise,
items will be prorated where 75% or more items for a
scale are present. Mechanisms for missing data on vari-
ables and key scales will be explored and a multiple im-
putation model built covering the primary analysis. Asensitivity analysis will explore the impact of employing
different missing data handling strategies.
Plans to give access to the full protocol, participant-level
data, and statistical code {31c}
Upon study completion, any party may apply to the
Chief Investigator for access to the full protocol,
participant-level data, and statistical code for academic
research purposes. An information governance commit-
tee will govern data access.
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
The TMG will include the Chief Investigator, CTRU,
and key external staff members, including two
individuals with acquired brain injuries from the PPI
group. TMG responsibilities will include clinical set-up
of the study, ongoing management, study promotion,
and planning for interpretation and dissemination of re-
sults. TMG meetings will be held quarterly as a mini-
mum. Further PPI will be provided by the trial’s PPI
group, which will include individuals from Different
Strokes, Stroke Association, and Headway charities.
The TSC will include an independent chairperson and
multiple independent members (including a PPI group
member, statistician, and person/s with clinical and trial
experience). TSC meetings will take place annually at a
minimum to monitor study progress and provide public,
clinical, and/or professional advice to TMG members. A
TSC sub-committee will review safety issues where
necessary.
Composition of the data monitoring committee, its role
and reporting structure {21a}
The CTRU at the University of Leeds will be responsible
for monitoring the quality and completeness of study
data, in accordance with Standard Operating Procedures
(SOPs) and Consolidated Standards of Reporting Trials
(CONSORT) guidelines. The TSC will be responsible for
reviewing clinical governance issues (in liaison with
NHS Trusts, if relevant), and any concerns warranting
modification or termination of the study. Decision to
terminate the study will be made by the TSC and
sponsor.
Adverse event reporting and harms {22}
Adverse events will be reported if classified as a Related
and Unsuspected Serious Adverse Event (RUSAE), i.e. an
event that is unexpected in severity and seriousness, and
suspected to be related to the study intervention. Possible
examples include accidental injury resulting from
workplace adaptations recommended by a RETAKE OT,
Radford et al. Trials         (2020) 21:1010 Page 13 of 17and/or work accidents resulting in injury and hospital
treatment.
Self-reported data on adverse events will be collected
at 3, 6, and 12 months post-randomisation, or via a site
notifying the CTRU or research team. Adverse events
will be immediately reported to the Chief Investigator,
who will take appropriate medical action, inform and
send follow-up information and reports to the REC, and
make necessary protocol amendments.
Frequency and plans for auditing trial conduct {23}
Investigators will notify the CTRU if there is a breach of
protocol or GCP principles likely to significantly affect
participants’ safety, health, and wellbeing, or scientific
value of the research.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
Important protocol amendments will be made by the
Chief Investigator, following consultation with the TMG
and any required approval from the REC and Research
and Development departments. Amendments will be
communicated to participants by the PI, and an
amended Informed Consent form completed.
Dissemination plans {31a}
Study findings will be disseminated, regardless of
direction or magnitude of effect, through journal
articles, conference presentations, and a peer-reviewed
NIHR HTA report submitted within 14 days of study
completion. Authorship decisions will be guided by jour-
nal criteria. Local collaborators will not have access to
study data until publication of the main findings. Partici-
pants, study investigators, and PPI group will be in-
formed of results via the study newsletter.
Discussion
The importance of supporting stroke survivors with
RTW is recognised in national policy and clinical
guidelines and is a UK government priority and NHS
outcome. However, a lack of evidence for the clinical-
and cost-effectiveness of stroke-specialist VR has im-
peded development and commissioning of VR services
for this population.
ESSVR is a complex intervention designed to support
stroke survivors to access, return to, and maintain
working roles in the 12months following a stroke. A
feasibility RCT [31] demonstrated that ESSVR (plus UC)
was more effective than UC alone for supporting RTW
among stroke survivors, and showed that the
intervention could be researched in NHS settings
alongside routine care. However, this was a single-centre
trial and results were not powered to determineeffectiveness. This protocol describes a multi-centre
RCT to determine the clinical- and cost-effectiveness of
ESSVR plus UC compared with UC alone.
RTW after stroke is considered a key rehabilitation
goal and an indicator of recovery [64]. The National
Stroke Programme was developed to achieve the aims of
the NHS Long Term Plan [25] and highlights that
improving access to VR will increase the number of
stroke survivors returning to work [65]. Despite this,
health services do not always routinely provide VR,
consider VR to be within their remit, or address stroke-
specific deficits that can impede successful RTW [66].
The need for provision of stroke-specialist VR is becom-
ing increasingly important, as there continue to be rises
in the incidence of stroke among younger people, retire-
ment age thresholds, and the societal costs of stroke.
This need is further compounded by the impending re-
cession and predicted twofold increase in UK unemploy-
ment rates resulting from the COVID-19 pandemic [15].
The National Stroke Strategy [18] and National Institute
of Health and Care Excellence (NICE) [19] both
recommend that VR be offered to stroke survivors in a
timely manner to enable reasonable and necessary
adjustments to be made to support their RTW. NICE
recommends identifying the demands of the working role
and the person’s impairments on work performance,
tailoring the VR intervention, educating employers about
the Equality Act 2010 and support available, conducting
workplace visits, and liaising with employers to establish
reasonable accommodations such as phased return or
equipment provision [19]. The ESSVR intervention
incorporates all of the above recommendations, but also
includes consideration of adjustments that can be made to
work roles/responsibilities, levels of supervision and
support, work preparation activities, and education for
stroke survivors, employers/co-workers, and families
about stroke-specific disabilities.
The lack of an approved VR pathway within local
areas has previously resulted in miscommunication,
inadequate training and knowledge of stroke and VR,
poor cross-service collaboration, and mild stroke pa-
tients receiving little or no support to RTW [66]. The
ESSVR intervention is innovative because it encourages
collaboration across the workplace and acute and com-
munity health services, an approach highly recom-
mended in the aftermath of the COVID-19 pandemic
[67]. Occupational therapists delivering the intervention
are specially trained to meet the needs of stroke survi-
vors wishing to RTW and encouraged to provide a flex-
ible and responsive service for as long as necessary up to
12months post-stroke. Individually tailored cross-service
interventions of this kind can be more costly in the
short-term. However, a pilot study for a similar interven-
tion among people with traumatic brain injuries
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only £75 greater per annum [68]. In addition, the long-
term cost benefits for this intervention could be high.
The 6-year follow-up (19 out of 43 participants) for the
feasibility RCT demonstrated that most stroke survivors
working at 12 months were still working 6 years later
(74%; n = 14) [37]. People who return to and stay in
work contribute more to the economy and are less likely
to experience and require expensive treatment for de-
pression [32, 69].
The ESSVR intervention has been designed in
accordance with the Medical Research Council’s
framework for developing and evaluating complex
interventions [70]. This multi-centre RCT includes an em-
bedded economic evaluation to estimate cost-effectiveness
and cost-utility analyses from NHS and PSS perspectives.
A mixed methods approach will be taken in the process
evaluation (reported elsewhere) to identify contextual fac-
tors influencing ESSVR implementation, RTW outcomes,
and roll-out within NHS stroke rehabilitation services. If
the ESSVR intervention was found to be clinically and
cost-effective and could be included as part of routine
NHS care, it would ensure stroke survivors of working age
have a meaningful rehabilitation endpoint (i.e. RTW).
RTW will also enable them to develop a sense of purpose,
establish routine, improve their self-worth, have greater fi-
nancial security, increase social contact, and contribute to
the economy [71].
There are various practical and operational issues to
consider in this study. For example, certain trial processes
may require adaptation to suit participants’ individual
needs, because stroke survivors can experience problems
with fatigue, concentration, attention, communication,
vision, and memory [2, 72]. This study includes
participants with strokes of varying severities; therefore,
research staff will need to be consistently attentive to each
participant’s mental capacity and their consent to take
part in the study. SMS text reminders and telephone calls
will be conducted to support timely completion of self-
report follow-up questionnaires, with involvement of
carers and/or telephone support where necessary. Poten-
tial barriers to intervention delivery and RTW may in-
clude lack of participant and/or employer engagement,
participants having limited insight into their disabilities,
and/or participants’ inability to return to previous working
roles. Such issues will be managed on a case-by-case basis
through regular discussions between RETAKE OTs and
mentors.
Therapists should receive training to equip them for
supporting stroke survivors to RTW [66]. In this study,
RETAKE OTs will receive a comprehensive 2-day training
package including an ESSVR manual, interactive work-
shops, and refresher days once recruitment has com-
menced. Tele-mentoring sessions will be providedmonthly with additional mentoring support as needed, to
support the OTs with clinical reasoning and help to en-
sure implementation fidelity. Competency assessments at
6 and 12 months into the intervention period will high-
light any further training and/or mentoring support needs.
The ESSVR intervention is a bespoke, manualised,
early vocational rehabilitation intervention and is not
routinely provided within pre-existing VR pathways. To
minimise the risk of contamination, a list of recruited
participants will be maintained to ensure RETAKE OTs
do not treat UC participants referred to their service
during the intervention period. Any potential contamin-
ation issues will be discussed between RETAKE OTs
and mentors and escalated to the Chief Investigator
where necessary. Similarly, the RETAKE OTs will be
able to receive support from the mentors and central
RETAKE team if they experience difficulty—or are un-
able to deliver the intervention due to personal or prac-
tical matters, such as caseload pressures, sickness, and
maternity leave. By offering this support, mentors and/or
the central RETAKE team will be able to protect the
health and wellbeing of the RETAKE OTs and ensure
the participant has ongoing ESSVR throughout the inter-
vention period.
The shift from a single-centre to a multi-centre
design also means that extra care will be needed to
ensure recruitment staff can recruit eligible partici-
pants within 12 weeks of their stroke. Prior to set-
up, site initiation visits and telephone meetings will
be conducted with therapy managers and other rele-
vant staff to ensure the site is able to deliver the
intervention. Staffing levels, recruitment targets, and
securing of backfill funding for local RETAKE staff
time will be included as topics of discussion during
such meetings.
The rising incidence of stroke among younger people,
the UK’s economic forecast, and clinical drivers
highlight the need for stroke survivors to receive support
to RTW. This RCT is a component of a programme of
work aimed at investigating the implementation of ESSV
R among stroke survivors of working age. Evidence for
the clinical- and cost-effectiveness of ESSVR would align
with political and clinical guidelines and support its roll-
out within NHS settings.Trial status
Protocol version 5.0, 18 February 2020. Recruitment for
the study commenced in May 2018 and was planned for
26 months. Challenges in trial delivery and the impact of
the COVID-19 pandemic meant that recruitment was
halted. The recruitment completion date is currently
under review, but it is estimated that this will take place
in December 2020.
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